glucagon-like-peptide-1-(7-36) and Overweight

We compared the efficacy and safety of beinaglutide, a glucagon-like peptide-1 (GLP-1) analogue with metformin in lowering the bodyweight of patients who were overweight/obese and non-diabetic.. Seventy-eight non-diabetic patients were randomly selected and beinaglutide or metformin was administered for 12 weeks. The primary endpoints were changes in body weight and the proportions of patients who lost≥5 and≥10% of their baseline body weights.. A total of 64 patients completed the study; patients in the beinaglutide group exhibited more bodyweight loss than those in the metformin group [(9.5±0.8%; 9.1±0.9 kg) and (5.1±0.9%; 4.5±0.8 kg), respectively, corresponding to a difference of approximately 4.5 kg (95% confidence interval, 2.2-6.9 kg;. Beinaglutide is more efficient than metformin at reducing weight and fat mass in patients who are overweight/obese and non-diabetic. Beinaglutide may be a useful therapeutic option for overweight/obesity control in the Chinese population.

Topics: Body Weight; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Obesity; Overweight; Peptide Fragments; Weight Loss

The aim of the present study was to establish the between-day reproducibility of fasting plasma GLP-17-36, glucagon, leptin, insulin and glucose, in lean and overweight/obese 8-11year-old boys. A within-group study design was utilised wherein the boys attended two study days, separated by 1week, where a fasting fingertip capillary blood sample was obtained. Deming regression, mean difference, Bland-Altman limits of agreement (LOA) and typical imprecision as a percentage coefficient of variation (CV %), were utilised to assess reproducibility between-days. On a group level, Deming regression detected no evidence of systematic or proportional bias between-days for all of the satiety-related analytes however, only glucose and plasma GLP-17-36 displayed low typical and random imprecision. When analysed according to body composition, good reproducibility was maintained for glucose in the overweight/obese boys and for plasma GLP-17-36, in those with lean body mass. The present findings demonstrate that the measurement of glucose and plasma GLP-17-36 by fingertip capillary sampling on a group level, is reproducible between-days, in 8-11year-old boys. Comparison of blood glucose obtained by fingertip capillary sampling can be made between lean and overweight/obese 8-11year-old boys. Presently, the comparison of fasting plasma GLP-17-36 according to body weight is inappropriate due to high imprecision observed in lean boys between-days. The use of fingertip capillary sampling in the measurement of satiety-related analytes has the potential to provide a better understanding of mechanisms that affect appetite and feeding behaviour in children.

Topics: Biomarkers; Blood Chemical Analysis; Blood Glucose; Body Composition; Child; Fasting; Fingers; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Leptin; Male; Overweight; Peptide Fragments; Regression Analysis; Reproducibility of Results; Satiation